Introduction
Organ transplantation is an effective therapy for many end stage diseases. A major complication associated with transplantation is allograft rejection which is controlled by administering immunosuppressive pharmacologic agents to allograft recipients; however, systemic immunosuppression often leads to opportunistic infections and drug-specific side-effects. Thus, there exists a great need to develop more specific immunosuppressive therapies. This goal may be achieved by delivering immunomodulatory signals specifically to the regions of antigen presentation. Gene transfer has the potential to introduce immunoregulatory molecules directly into the graft, producing a localized immunosuppressive environment without systemic side-effects. 1, 2 The major factor limiting the success of gene therapy is that transferred genes are expressed only transiently and at low levels in only a small number of target cells. 3 However, these factors may not be deleterious in transplantation applications. 4 The transient expression of a gene following graft placement may provide the appropriate signals to prevent the initiation of an immune Correspondence: LA DeBruyne Received 13 November 1997; accepted 9 March 1998 response and induce tolerance. In addition, transfection of only a small number of cells may be efficient when transferring genes encoding soluble, secreted immunosuppressive molecules.
IL-10 is an important regulatory molecule that possesses immunosuppressive activity and was originally identified by its ability to inhibit cytokine synthesis of Th1 cells, which produce IFN-␥ and IL-2 and mediate DTH responses and CTL development. 5 IL-10 is predominately produced by macrophages and Th2 cells. Th2 cells produce IL-4, IL-5 and IL-10 which promote humoral, mucosal and allergic responses. 6 Th1 and Th2 cells are antagonistic such that IFN-␥ promotes Th1 development and inhibits Th2 proliferation. In contrast, IL-10 inhibits cytokine production by Th1 cells but not Th2 cells. 7 It has been proposed that IL-10 mediates this activity by inhibiting IL-12 production, a key regulatory cytokine in promoting Th1 development. 8, 9 It should be noted that IL-10 also inhibits the production of monokines, including IL-1, IL-6, IL-8, TNF-␣, GM-CSF and G-CSF. 10, 11 In addition to inhibiting cytokine production, IL-10 has also been shown to block accessory cell function of macrophages by down-regulating MHC class II expression and decreasing expression of the costimulatory molecule B7. [12] [13] [14] [15] As a result of these activities, IL-10 is a potent suppressor of effector functions of macrophages and T cells. However, in addition to regulating immune responses negatively, IL-10 also has growth factor activity and promotes the proliferation and differentiation of B cells, mast cells and thymocytes. [16] [17] [18] A homologue of IL-10 encoded in the Epstein-Barr BCRF I open reading frame, designated viral IL-10, has activity on both human and mouse cells. 19 Viral IL-10 shares many of the biologic activities of cellular IL-10, including inhibition of cytokine synthesis and accessory cell function. 5, 10, 12 However, vIL-10 does not posses the T cell costimulatory activities of cellular IL-10. [20] [21] [22] Thus, the introduction of vIL-10 into allografts by direct gene transfer should reduce immunogenicity, impair effective antigen presentation, and suppress macrophage and T cell effector function, thereby inhibiting graft rejection.
Previous studies from our laboratory showed that a variety of plasmid and viral (retrovirus, herpesvirus, adenovirus) vectors can successfully transfer and express exogenous genes in cardiac allografts. 1, 2, 23, 24 The duration and distribution of transferred gene expression depended on vector characteristics. These studies showed that the transient, local expression of the gene encoding vIL-10 can generate local immunosuppression by inhibiting donor-specific HTL and CTL, making gene transfer a therapeutic option for preventing allograft rejection. These previous studies utilized the nonvascularized, neonatal heart, ear pinna model. Although informative, this model system is not directly clinically applicable. Thus, the present study addresses the plausibility of utilizing vIL-10 gene transfer in a clinically relevant vascularized model.
The development of effective vectors for vascular gene delivery is an absolute requisite if gene therapy approaches are to be successful in solid organ transplantation. Although adenoviral vectors have been shown to be effective for such purposes in animal models, the ability to achieve comparable gene transfer efficiency with nonviral vectors would be safer, less toxic, and more applicable to humans. A new cationic liposome preparation, designated ␥AP-DLRIE/DOPE, is an efficient liposomal vector that has recently been shown to increase in vivo vascular gene expression by greater than 15-fold compared with naked DNA or previously described cationic lipids. 25 These levels of gene expression represent a significant improvement in nonviral vector in vivo transfection efficiency and approach levels observed with clinically acceptable doses of adenoviral vectors. 25 Thus, the present study utilizes ␥AP-DLRIE/DOPE to deliver in situ a vIL-10 encoding plasmid to the vasculature of donor cardiac allografts and identifies immunologic mechanisms associated with enhanced graft survival.
Results
vIL-10 gene transfer and expression in cardiac allografts BALB/c cardiac allografts were perfused with different doses of plasmid DNA encoding vIL-10 complexed with ␥AP DLRIE/DOPE, and graft survival was determined following transplantation into C57BL/6 recipient mice ( Table 1 ). The total amount of plasmid DNA utilized and the ratio of DNA to lipid both influenced graft survival. High lipid concentrations (Ͼ600 g/ml) resulted in vascular hemorrhage, which may have been an indication of lipid toxicity. As shown in Table 1 , graft survival improved as the total amount of DNA and the DNA:lipid charge ratio increased. For these studies, optimal gene transfer (as measured by enhanced graft survival) was demonstrated at a dose of 1500 g/ml DNA combined with 500 g/ml lipid, which significantly prolonged graft survival compared with controls (16.0 days versus 8.14 days, P = 0.02) and was used in the remainder of these studies. It was not possible to increase further the DNA: lipid ratio, since a ratio of 4.0 at high DNA-lipid concentrations resulted in precipitation of the complex. As a control for DNA-lipid effects, donor cardiac allografts were perfused with DNA-liposome complexes encoding vIL-10 in the antisense orientation. As shown in Table 2 , there was no significant difference in graft survival between unmodified allografts and antisense controls (P = 0.72). In addition, animals receiving vIL-10-transduced grafts treated with an anti-vIL-10 mAb, which does not cross-react with cellular murine IL-10, rejected their grafts similarly to controls, demonstrating that expression of the vIL-10 transgene was required for prolonged graft survival.
To address the question of intragraft transgene expression, RT-PCR analysis was performed on the donor hearts of animals receiving vIL-10-transduced grafts. Animals were killed and donor heart tissue analyzed by RT-PCR on days 1, 7 and 14 while the hearts were still functioning, as indicated by abdominal palpation. All hearts evaluated expressed the vIL-10 transgene (Figure 1 ). Although these PCR assays were not quantitative, expression appeared strongest early on (day 1) and was harder to detect further out (day 14). Since donor allografts perfused with vIL-10 DNA-liposome complexes were not flushed clear of vector before anastomosis of the graft into the recipient, it was likely that some vIL-10 plasmid DNA localized to other anatomic regions in addition to the graft. It was therefore important to determine if vector DNA outside the graft contributed to graft survival and immunosuppression by gene expression. RT-PCR analysis on liver, lung, kidney, spleen, mesenteric lymph nodes, and native heart from animals receiving vIL-10-transduced grafts detected vIL-10 expression in all tissues at 7 days after transplantation, albeit at low levels in most samples (Figure 2) . However, by 14 days All donor grafts were perfused with 250 l of the optimal DNA:lipid complex (1500 g/ml DNA:500 g/ml lipid). a Five animals were killed on day 14 with functioning grafts which were used for immunologic analysis. These animals were included in the calculation of the mean survival and given a day 14 value, resulting in a mean of greater than 16 days. after transplantation vIL-10 gene transcription was only detectable in the allograft. Greater gene transfection might be expected within the graft since the allograft remained in contact with the DNA-lipid complexes for an extended time-period under static conditions, whereas upon anastomosis the remaining plasmid DNA was flushed out of the allograft and into the bloodstream.
Figure 1 Viral IL-10 transgene transcription in cardiac allografts. RT-PCR was performed on
Viral IL-10 gene transfer decreases intragraft and systemic donor-specific cell-mediated immunity Limiting dilution analysis was performed on graft infiltrating cells and splenocytes to investigate the immunologic effects of vIL-10 gene transfer. A modification of this assay was used that allows for the differentiation between the total number of precursor donor-reactive T lymphocytes (tHTL and tCTL) and in vivo activated or 'conditioned' donor-reactive T lymphocytes (cHTL and cCTL). These analyses were performed at least three times on vIL-10 sense and antisense control animals on days 7 and 14 after transplantation. It should be noted that it was not possible to assess graft infiltrating HTL and CTL in antisense control grafts on day 14, since by that point the grafts which had rejected on days 8 or 9 had become masses of necrotic tissue that did not yield appreciable numbers of graft infiltrating cells for immunologic analysis. Limiting dilution analysis of graft infiltrating cells on day 7 after transplant revealed no difference in the total number of donor-specific graft infiltrating tHTL or cHTL compared with antisense controls (Figure 3a) . However, by day 14 after transplant, there was a significant decrease in the number of both donor-specific cHTL and tHTL infiltrating the graft in vIL-10-transduced hearts compared with day 7 sense and antisense controls. This decrease in HTL numbers was detectable in three of three experiments. The observed local decrease in graft infiltrating HTL in vIL-10-transduced recipients correlated with a reduction in donor-specific splenic HTL ( Figure 3c ). On day 7 after transplant, the number of donor-specific splenic HTL in vIL-10-transduced recipients was similar to antisense controls, although by day 14 these numbers dropped significantly in the experimental group. In contrast, the number of splenic cHTL and tHTL in antisense controls remained constant between days 7 and 14, as has been previously reported in animals receiving unmodified allografts. 26 In summary, vIL-10 gene transfer resulted in a transient infiltration of donorspecific HTL in the allograft which subsided by day 14 after transplant, correlating with a decrease of donorspecific HTL in the spleen.
Analysis of graft infiltrating cytolytic cells on day 7 revealed that fewer donor-specific cCTL and tCTL infiltrated vIL-10-transduced grafts compared with controls, and that this decrease persisted on day 14 ( Figure 3b ). Although this decrease was small (2.6-fold) it was reproducible in three of three experiments. Limiting dilution analysis of splenocytes from antisense controls showed a marked expansion of tCTL on day 7 after transplant ( Figure 3d ), which also normally occurs in recipients of unmodified allografts. 26 This expansion of donor-specific tCTL was not present in animals receiving vIL-10-transduced grafts. The expansion of splenic tCTL in antisense controls subsided by day 14 after transplant, as has been
Figure 3 Limiting dilution analysis of donor-specific cells. A modification of this assay was used that allows for the differentiation between the total number of precursor donor-reactive T lymphocytes (tHTL and tCTL) from those that have been activated or 'conditioned' in vivo (cHTL and cCTL). Results are presented as number per one million cells, including the 95% confidence interval. (a) Graft infiltrating donor-specific HTL; (b) graft infiltrating donor-specific CTL; (c) splenic donor-specific HTL; (d) splenic donor-specific CTL.
reported in recipients of unmodified allografts. 26 Activated splenic CTL were rare in both controls and in animals with vIL-10-transduced grafts. Thus, these findings reveal that vIL-10 gene transfer results in a modest decrease in graft infiltrating cCTL and tCTL, and inhibits splenic tCTL expansion.
Viral IL-10 gene transfer is associated with decreased alloantibody production
The decrease in the number of graft infiltrating helper T cells suggested that there might be a concomitant decrease in donor-specific alloantibody production ( Table 3 ). The results show that animals receiving vIL-10 perfused donor hearts produced significantly less IgM alloantibody at days 7 and 14 compared with both antisense and unmodified controls. In fact, significant levels of donor-specific IgM alloantibody were only detectable in serum samples from mice receiving suboptimal vIL-10-transduced grafts that did not exhibit prolonged survival. Animals that received donor grafts transduced with the optimal DNA and lipid doses and then treated with an anti-vIL-10 mAb also produced high levels of IgM allo- Alloantibody results are presented as mean channel fluorescence. All groups were treated with the optimal 3.0 DNA:Lipid ratio of vIL-10 sense plasmid to ␥AP DLRIE/DOPE, unless otherwise indicated.
antibody, further indicating that vIL-10 is directly responsible for inhibiting donor-specific IgM alloantibody production. One potential mechanism by which vIL-10 gene transfer may induce prolonged graft survival is by inducing a Th2-type immune response. Differential production of Th1 and Th2 cytokines can be reflected in alloantibody isotype production. IgG1 is indicative of a Th2-type response, whereas IgG2a is indicative of a Th1-type immune response. In these studies, little to no IgG of either isotype was detectable in animals receiving donor grafts transduced with the optimal DNA-lipid dose. However, large amounts of both IgG1 and IgG2a were detected in both antisense and unmodified controls, as well as in animals receiving suboptimal DNA and lipid doses or in animals treated with anti-vIL-10 mAb. In the animals that exhibited IgG production, there was no dominant isotype produced; all animals exhibited comparable amounts of IgG1 and IgG2a.
vIL-10 gene transfer is associated with fibrosis of cardiac allografts Donor syngeneic and allogeneic cardiac grafts were fixed in formalin, sectioned, and stained with either hematoxylin and eosin or trichrome for examination by light microscopy ( Figure 4 ). Prolonged survival of vIL-10-transduced allografts was associated with a novel histology characterized by a moderate mononuclear infiltrate composed largely of unactivated cells, as distinguished by their low cytoplasm to nucleus ratio, marked edema, and diffuse collagen deposition in the interstitium (as indicated by trichrome staining); yet myocytes remained viable and vessels were patent (Figure 4e and f) . Since it has been reported that cellular IL-10 up-regulates elastin gene expression in vivo, elastin stains were also performed, but there was no indication of abnormal elastin production (data not shown). 27 These manifestations did not occur in syngeneic grafts perfused with the vIL-10 DNA-liposome complexes (Figure 4g and h), implying that the observed fibrosis was not a direct effect of the vIL-10 gene product, lipid-associated toxicity, or an artifact of the perfusion protocol. In addition, there was no evidence of fibrosis in allografts perfused with antisense vIL-10 DNA-liposome complexes (Figure 4c and d) . These findings suggest that both the vIL-10 transgene product and an alloantigenic component are required for the observed effect.
Discussion
This study addressed the feasibility of utilizing vIL-10 gene transfer as a therapeutic modality for inhibiting cardiac allograft rejection in a clinically relevant model and addressed the immunomodulatory mechanisms associated with enhanced graft survival. Lipid-mediated gene transfer of vIL-10 was shown to significantly prolong allograft survival without conventional immunosuppression and the effect was specific in that antisense constructs or treatment with an anti-vIL-10 mAb negated the effect. The present study did not examine the specific cell types transduced or the precise location of transgene expression. However, previous in vivo studies of lipidmediated gene transfer to pig vasculature using lipofectin or ␥AP DLRIE/DOPE demonstrated that transfection was site limited and resulted in reporter gene expression 
Figure 4 Prolonged survival of vIL-10 transduced allografts was associated with a novel histology characterized by a moderate and quiescent mononuclear infiltrate, marked edema, and diffuse collagen deposition throughout the interstitium. Grafts were sectioned and stained with either hematoxylin and eosin (a, c, e and g) or trichrome (b, d, f and h) for examination by light microscopy (×400). Collagen deposition (bright blue) is visible in trichrome-stained tissue sections. (a) and (b), vIL-10 sense allografts at day 7 after transplant; (c) and (d), vIL-10 antisense allografts at day 7 after transplant; (e) and (f), vIL-10 sense allografts at day 14 after transplant; (g) and (h), vIL-10 sense syngeneic grafts at day 14 after transplant.
in vessel endothelial cells and smooth muscle cells. 25, 28 This is in agreement with reports using lipofectin in the vascularized mouse cardiac transplant model. 29, 30 Using a luciferase transgene, investigators reported that perfusion of DNA-liposome complexes via the coronary arteries resulted in expression of the transgene primarily in the coronary capillaries, in perivascular areas surrounding coronary arteries and veins, and the endocardia of both ventricles.
Other studies using adenoviral vectors have perfused cardiac allografts and isografts and shown similar reporter results, except that adenoviral transgene expression was not confined to the coronary vasculature (including endothelial cells and smooth muscle cells of the vessels), but was also present in the myocytes. [31] [32] [33] [34] The higher efficiency of viral vectors at delivering genes in vivo than nonviral vectors is illustrated by a direct comparison in which luciferase transgene activity was 10-fold higher in rat cardiac grafts transduced with an adenoviral vector compared with a plasmid vector. 35 None the less, even with viral vectors, investigators have documented inefficient gene transfer by allograft perfusion, with most studies reporting less than 1% of the cells expressing the transgene. 30, 33 Although appealing because they can transduce a wide variety of cell types relatively efficiently, adenoviral vectors induce an exuberant immune response and can be especially problematic in human gene therapy applications, in that many individuals have pre-existing immunity to adenovirus. 3 Our laboratory recently demonstrated that the vIL-10 transgene can inhibit not only alloantigenic responses, but also antiadenoviral immune responses. 36 The results showed that in vivo treatment with a vIL-10 expressing adenoviral vector prevented adenovirus-specific CTL priming and generation. Not only did the vIL-10 gene product inhibit the immune response toward adenoviral antigens, it improved the persistence of the vector and extended transgene expression. Thus, the efficacy of viral vectors may be further improved by incorporating immunosuppressive genes, such as vIL-10, into the vector.
Although vIL-10 gene transfer prolonged graft viability, survival was not indefinite and tolerance was not achieved. This was likely due to the fact that lipidmediated plasmid gene transfer was inefficient and expression was low and transient. Even though viral vector gene transfer may be more efficient than plasmidbased vectors, plasmids are likely to be safer and more clinically applicable to transplantation and thus deserving of continued testing and scrutiny. Additional approaches will be required to improve gene transfer and expression such as optimization of nucleic acid delivery, transcellular transport, nuclear localizing signals and selective promoters. 1, 3, 4, 25 We previously demonstrated that a number of plasmid and viral vectors could successfully transfer and express vIL-10 in cardiac transplants. 1, 2 These past studies utilized the neonatal heart, ear pinna model. In this nonvascularized model, retroviral vectors encoding vIL-10 were found to prolong significantly allograft survival and inhibit donor-specific CTL and HTL as well as CD4
+ and CD8 + lymphocytic infiltration within the graft. 2 In the present study, which uses a vascularized cardiac allograft model, we detected only a slight decrease in the number of donor-specific CTL, but did find a marked decrease in donor-specific intragraft and splenic IL-2 producing HTL. The large decrease demonstrated in both intragraft cHTL and tHTL at day 14 after transplant might suggest a decrease in the absolute number of T cells present, as a result of deletion or anergy. An alternative explanation for this finding is that since vIL-10 is known to induce Th2 cells, donor-specific HTL may have had a change of function, now producing IL-4 instead of IL-2 in response to donor alloantigen. These separate mechanisms are not necessarily mutually exclusive. Limiting dilution analysis of splenocytes from these animals indicated that there was also a detectable decrease in the number of donorspecific tHTL from 1/4849 on day 7 to 1/33 573 on day 14 after transplantation in the spleens of these animals. This demonstrates not only local, intragraft immunosuppression, but also a systemic immunosuppressive effect as well, and makes it unlikely that the decrease in intragraft HTL was due to egress of HTL from the graft into the systemic lymphocyte pool. In addition, the fact that vIL-10 gene transfer inhibited splenic expansion of donor-specific tCTL further suggests systemic, donorspecific immunosuppression. Future studies will focus on differentiating the mechanisms responsible for decreased donor-specific HTL and CTL numbers, and their influence on graft survival.
Mechanistically, vIL-10 gene transfer resulted in decreased alloantibody production with little to no IgG class switching. Viral IL-10 is a known growth factor for B cells and has been shown to increase antibody production in vivo. 17 Thus, it is unclear why vIL-10 gene transfer resulted in inhibition of alloantibody production. Possibly other biologic effects of vIL-10, such as blocking accessory cell function by down-regulating MHC class II expression and decreasing expression of the costimulatory molecule B7, impair effective antigen presentation and T cell helper function. None the less, it is clear from findings in this study that vIL-10 gene transfer can inhibit both humoral and cellular components of the immune response.
Our findings are in contrast to reports that expression of an IL-10 transgene in pancreatic islets did not inhibit allograft rejection or autoimmunity. 21, 37, 38 However, these studies utilized cellular IL-10 which possesses immunostimulatory activities, including enhancing MHC class II expression and inducing cytotoxic T cell differentiation, that are not properties of vIL-10. In addition, recent studies have shown that both vIL-10-transduced islets and hepatic allografts produce biologically relevant amounts of vIL-10 that inhibit alloantigenic lymphocyte proliferation in vitro. 39, 40 Furthermore, it was reported that mice receiving vIL-10-transduced allogeneic tumors develop local anergy to the tumors, whereas mice receiving the same allogeneic tumors transduced with cellular IL-10, suppress tumor growth and frequently reject the tumor. 22 Finally, a direct comparison in our laboratory utilizing retroviral vectors encoding either vIL-10 or cellular IL-10 demonstrated that treatment of nonvascularized cardiac allografts with vIL-10 retrovirus results in enhanced graft survival (27.6 days) whereas retroviral cellular IL-10 has no effect on prolonging survival (12.0 days) compared with controls (12.1 days). 2 These findings contrast the immunologic effects of vIL-10 and cellular IL-10 and suggest that local vIL-10 production, but not cellular IL-10, can suppress immune reactivity in response to alloantigen.
While vIL-10 gene transfer inhibited alloantigenspecific immune responses and prolonged graft survival, it was also associated with an unusual microscopic pathology. Viral IL-10-transduced allografts were characterized by a moderate mononuclear infiltrate, marked edema, and diffuse collagen deposition. These manifestations did not occur in syngeneic grafts perfused with the vIL-10 DNA-lipid complexes or allogeneic grafts perfused with vIL-10 antisense DNA-lipid complexes. This implies that the observed fibrosis was not a direct effect of the vIL-10 transgene product or lipid carrier, but that a response to an alloantigenic component is necessary. It might be postulated that vIL-10 inhibits only part of the allogeneic response and thus 'unmasks' a response resulting in the observed pathology. Little is known about the role of IL-10 in fibrosis. Reitamo et al 27 reported that cellular IL-10 can up-regulate elastin gene transcription, yet in the present study, we found no indication of abnormal elastin production. Other reports have indicated that cellular IL-10 inhibits postoperative intraperitoneal adhesion formation and activation of coagulation and fibrinolysis during human endotoxemia, suggesting that IL-10 down-regulates fibrotic processes. 41, 42 At present, it is not clear what is inducing the fibrosis in our model, but one possible candidate may be TGF␤. TGF␤ plays a role in promoting Th2 helper cells by inhibiting Th1 development, and is a prominent inducer of fibrosis. 43, 44 Because TGF␤ itself possesses many immunosuppressive properties, we have transduced cardiac allografts with viral and nonviral vectors encoding TGF␤ in the nonvascularized ear-heart model. 1, 23, 24 In this system, we have demonstrated that TGF␤ gene transfer prolongs allograft survival (26.3 days versus 12.6 days for controls) but does not induce any apparent fibrosis. 23 Yet preliminary results with TGF␤ lipid-mediated gene transfer in the vascularized heart model demonstrated marked fibrosis of TGF␤-transduced grafts (LD, JB, KB, unpublished). In addition, it was reported that in vivo gene transfer of TGF␤ into kidneys induced glomerulosclerosis, characterized by extracellular matrix accumulation. 45 Thus, future studies are aimed at determining the nature of the observed fibrosis. This is an important issue in that vIL-10-transduced grafts appear to succumb to edema and fibrosis rather than traditional immunologic rejection. Perhaps, if the fibrosis could be inhibited then vIL-10 gene transfer may be much more effective at prolonging graft survival. ) mice were purchased from The Jackson Laboratory (Bar Harbor, ME, USA). All mice used were between 8 and 12 weeks of age.
Materials and methods

Animals
Medium
The culture medium used in these studies was DMEM supplemented with 1.6 mm l-glutamine, 0.27 mm lasparagine, 10 mm Hepes buffer, 1.0 mm sodium pyruvate, 100 U/ml penicillin/streptomycin (all obtained from Gibco, Grand Island, NY, USA) and 5 × 10 −5 m 2-ME (Sigma Chemical, St Louis, MO, USA). For limiting dilution microcultures, medium was supplemented with 10% heat inactivated fetal calf serum (Hyclone, Logan, UT, USA).
Plasmids and lipid
The plasmids pMP6AvIL-10(s) and pMP6AvIL-10(as) were constructed which encode the immunosuppressive cytokine viral IL-10, under the control of the HCMVie promoter, in the sense and antisense orientation, respectively. 46 Plasmid DNA was combined with the cationic lipid N- (3-aminopropyl) -N,N-dimethyl-2,3-bis(dodecyloxy)-1-propaniminium bromide/dioleoyl phosphatidylethanolamine (␥AP DLRIE/DOPE), which was generously provided by VICAL (San Diego, CA, USA). DNAliposome complexes were diluted in lactated Ringer's solution and incubated for 10 min at room temperature before being perfused into donor hearts.
Lipid-mediated gene transfer of cardiac allografts Heterotopic cardiac transplantation was performed by anastomosing BALB/c donor hearts to the great vessels in the abdomen of C57BL/6 recipients as described by Corry et al. 47 For vIL-10 gene transfer, donor hearts were perfused in situ by ligating the venae cavae to retain the perfusate. The distal aortic arch was then ligated and held in position by the suture to facilitate perfusion of the coronary vasculature via the aortic root with a 1 cc syringe and a 30-gauge needle. The donor heart was first flushed with 400 l of room temperature heparin (250 U/ml), then perfused with 250 l of room temperature DNA-liposome complexes in lactated Ringer's solution. Following perfusion, donor grafts were immediately harvested and placed in iced Ringer's solution for approximately 1 h and then transplanted without further perfusion or wash out. In this model, the transplanted heart resumes contractions until acutely rejected, which occurs in this strain combination in 8-9 days. Transplant function was monitored by daily abdominal palpation, and statistical comparison was performed with a Student's t test. For histological analysis, cardiac allografts were fixed in formalin, sectioned at 5 mm, and stained with either hematoxylin and eosin or trichrome for examination by light microscopy.
Anti-vIL-10 mAb treatment Animals receiving vIL-10-transduced cardiac allografts were injected i.p. on days 0, 1 and 2 after transplant with 800 g of the purified rat anti-human IL-10 mAb JES3-19F1.1.1 (American Type Culture Collection, Rockville, MD, USA) that neutralizes vIL-10 but does not cross-react with murine cellular IL-10.
48
Recovery of heart infiltrating cells Hearts were removed, minced and digested with 1 mg/ml collagenase A (Boehringer Mannheim Biochemicals, Indianapolis, IN, USA) for 30 min at 37°C. Heart infiltrating cells were washed free of collagenase and viable leukocytes enumerated by trypan blue exclusion.
Limiting dilution analysis of helper T lymphocytes Two related techniques were used which distinguish in vivo stimulated or 'conditioned' alloantigen-reactive helper T lymphocytes (cHTL) from total precursor helper T lymphocytes (tHTL). 49 For tHTL, dilutions of recipient cells were added as responder cells to microtiter wells along with gamma irradiated (5000 R) allogeneic splenocyte stimulator cells and incubated for 16 h. CTLL-20 cells (an IL-2-dependent line) were then added directly to the microcultures, in order to detect IL-2 produced by the responder cells. The microcultures were incubated for an additional 24 h, including a 16 h terminal pulse with 3 Hthymidine before harvesting by aspiration on to filter mats. For cHTL, recipient responder cells were gamma irradiated (2000 R) before addition to microcultures. After the addition of irradiated (5000 R) allogeneic stimulator cells, CTLL-20 cells were added at the initiation of culture and microcultures were pulsed with 3 H-thymidine, incubated overnight and harvested. For both tHTL and cHTL, 3 H-thymidine incorporation was determined on a scintillation counter. Individual microcultures were considered positive for IL-2 production if Limiting dilution analysis of cytolytic T lymphocytes LDA techniques were used which distinguish in vivo stimulated alloantigen-reactive cells (cCTL) from unstimulated total precursor cells (tCTL) with the same alloantigen specificity. 50 For tCTL, dilutions of recipient cells were added to microtiter wells along with gamma irradiated (5000 R) allogeneic splenic stimulator cells and incubated for 7 days. To detect cytolytic activity, 51 Crlabeled BALB/c splenocyte concanavalin A blasts were added as target cells to the microcultures. Following a 4 h incubation, microculture supernatants were assayed for release of 51 Cr in a gamma counter. For cCTL, the same 7 day culture conditions were employed except that irradiated (5000 R) syngeneic splenocytes were used in place of allogeneic splenic stimulator cells. Since no stimulating alloantigens were present in the modified LDA microcultures, only those CTL which had received an allogeneic stimulus before the analysis could demonstrate detectable cytolytic activity. Both tCTL and cCTL microcultures were considered cytolytic if observed chromium release was greater (mean plus 3 s.d.) than the chromium release observed in wells that contained target cells and stimulator cells but no responder cells.
Limiting dilution analysis
Minimal estimates of HTL or CTL frequency were obtained according to the Poisson distribution equation as the slope of a line relating the number of responder cells per microwell (plotted on a linear x-axis) and the percentage of microwells that failed to produce IL-2 or develop cytolytic activity, respectively (plotted on a logarithmic y-axis). The slope of this regression line was determined by computer using 2 minimization analysis, as described by Taswell. 51 This analysis yields the minimal frequency estimate, the 95% confidence interval of the frequency estimate, and a 2 estimate of probability.
RNA isolation and cDNA synthesis Cardiac allografts were homogenized in 1 ml RNAzol B (Teltest, Friendswood, TX, USA), which utilizes guanidinium thiocyanate to isolate total RNA. RNA was extracted with chloroform/isoamyl alcohol, precipitated with isopropanol, and washed with 70% ethanol. RNA was incubated with DNase at 37°C for 15 min then extracted with phenol/chloroform/isoamyl alcohol, precipitated with ethanol, and washed with 70% ethanol. RNA was quantified using a spectrophotometer, and cDNA was obtained by random primer reverse transcription of 1 g of DNAse-treated RNA.
DNA isolation DNA was isolated by homogenizing tissues in 1 ml of TRIzol (GIBCO BRL-Life Technologies, Grand Island, NY, USA). DNA was extracted from the interphase and ethanol precipitated. DNA pellets were washed with 0.1 m sodium citrate in 10% ethanol, followed by 75% ethanol. DNA pellets were then resuspended in 8 mm NaOH and quantified using a spectrophotometer.
Polymerase chain reaction (PCR)
One microgram quantities of DNA or cDNA were amplified by PCR using two primers specific for the vIL-10 gene, 5′-ATGGAGCGAAGGTTAGTGGTC-3′ (upstream) and 5′-ACTCTTGTTCTCACACGGCAG-3′ (downstream), which yield a 387 bp fragment. The PCR cycle used was 96°C for 15 s, 60°C for 30 s, and 72°C for 2 min. After 30 cycles, PCR products were run on 1.8% agarose gels and visualized by ethidium bromide staining.
Alloantibody isotype P815 cells (H-2 d
) were stained for FACS analysis using a 1:50 dilution of recipient serum as the primary antibody, followed by FITC-conjugated isotype-specific secondary antibodies. FITC-conjugated, affinity purified sheep antimouse IgM, IgG1 and IgG2a were obtained from The Binding Site (San Diego, CA, USA). Data are presented as the mean channel fluorescence determined on a Becton Dickinson FACScan (San Jose, CA, USA).
